Support data with Adalimumab in patients with rheumatoid arthritis in Germany

被引：0
|
作者：
Tony, H-P
Hein, G.
Richter, C.
Dockhorn, R.
Spieler, W.
Sprekeler, R.
Zeise E.
Matiba, B.
机构：
[1] Univ Wurzburg, Klin Immunol, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Univ Jena, Innere Med Klin, D-6900 Jena, Germany
[3] Rheumatol Schwerpunktpraxis, Stuttgart, Germany
[4] Rheumatol Schwerpunktpraxis, Weener, Germany
[5] Rheumatol Schwerpunktpraxis, Zerbst, Germany
[6] Rheumatol Schwerpunktpraxis, Zeven, Germany
[7] Abbott, Med Abt, Wiesbaden, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：83 / 84
页数：2
相关论文
共 50 条
  • [31] Adalimumab for treating rheumatoid arthritis
    Navarro-Sarabia, F
    Ariza-Ariza, R
    Hernandez-Cruz, B
    Villanueva, I
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03):
  • [32] Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
    Mease, Philip
    Mittal, Manish
    Skup, Martha
    Davis, Matthew
    Ganguli, Arijit
    Johnson, Scott
    Schiff, Michael
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [33] Adalimumab in the treatment of rheumatoid arthritis
    Voulgari, Paraskevi V.
    Drosos, Alexandros A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (04) : 549 - 561
  • [34] Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
    Taylor, Peter
    Keystone, Edward
    Ortmann, Robert
    Issa, Maher
    Xie, Li
    Muram, David
    Bradley, John
    de Bono, Stephanie
    Rooney, Terence
    Tanaka, Yoshiya
    Faraawi, Rafat
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 890 - 891
  • [35] Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
    Taylor, Peter C.
    Keystone, Edward
    Ortmann, Robert
    Issa, Maher
    Xie, Li
    Muram, David
    Bradley, John D.
    de Bono, Stephanie
    Rooney, Terence
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany; [Kosten-Nutzen-Bewertung von Adalimumab bei Rheumatoider Arthritis in Deutschland]
    Gissel C.
    Götz G.
    Repp H.
    Zeitschrift für Rheumatologie, 2016, 75 (10) : 1006 - 1015
  • [37] METHOTREXATE REDUCES IMMUNOGENICITY IN ADALIMUMAB TREATED RHEUMATOID ARTHRITIS PATIENTS
    Krieckaert, C.
    Nurmohamed, M. T.
    Wolbink, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 101 - 102
  • [38] Bioavailability of adalimumab following subcutaneous injections in rheumatoid arthritis patients
    Velagapudi, R
    Noertershauser, P
    Awni, W
    Granneman, R
    Kupper, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P84 - P84
  • [39] Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
    Zamora-Atenza, Carlos
    Diaz-Torne, Cesar
    Geli, Carme
    Diaz-Lopez, Cesar
    Ortiz, M. Angels
    Moya, Patricia
    Castellvi, Ivan
    Nieto, Juan C.
    Canto, Elisabet
    Casademont, Jordi
    Juarez, Candido
    Llobet, Josep M.
    Vidal, Silvia
    ARTHRITIS RESEARCH & THERAPY, 2014, 16 (04)
  • [40] CLINICAL USEFULNESS OF SERUM LEVEL OF ADALIMUMAB, IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Rosas, J.
    LLinares, F.
    de la Torre, I.
    Valor, L.
    Barber, X.
    Santos-Ramirez, C.
    Hernandez, D.
    Senabre, J. M.
    Carreno, L.
    Santos-Soler, G.
    Salas, E.
    Sanchez-BArrioluengo, M.
    Molina-Garcia, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 233 - 234
12345